News
Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...
12h
Zacks.com on MSNNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowNovavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...
Fintel reports that on June 17, 2025, Citigroup initiated coverage of Novavax (NasdaqGS:NVAX) with a Sell recommendation.
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...
Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...
Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...
The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...
7d
Zacks Investment Research on MSNNovavax's COVID-Flu Combo Shot Shows Strong Immune ResponseNovavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...
US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results